Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review.
Journal
JAMA surgery
ISSN: 2168-6262
Titre abrégé: JAMA Surg
Pays: United States
ID NLM: 101589553
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
pubmed:
1
7
2021
medline:
28
1
2022
entrez:
30
6
2021
Statut:
ppublish
Résumé
The incidence of early-onset colorectal cancer (younger than 50 years) is rising globally, the reasons for which are unclear. It appears to represent a unique disease process with different clinical, pathological, and molecular characteristics compared with late-onset colorectal cancer. Data on oncological outcomes are limited, and sensitivity to conventional neoadjuvant and adjuvant therapy regimens appear to be unknown. The purpose of this review is to summarize the available literature on early-onset colorectal cancer. Within the next decade, it is estimated that 1 in 10 colon cancers and 1 in 4 rectal cancers will be diagnosed in adults younger than 50 years. Potential risk factors include a Westernized diet, obesity, antibiotic usage, and alterations in the gut microbiome. Although genetic predisposition plays a role, most cases are sporadic. The full spectrum of germline and somatic sequence variations implicated remains unknown. Younger patients typically present with descending colonic or rectal cancer, advanced disease stage, and unfavorable histopathological features. Despite being more likely to receive neoadjuvant and adjuvant therapy, patients with early-onset disease demonstrate comparable oncological outcomes with their older counterparts. The clinicopathological features, underlying molecular profiles, and drivers of early-onset colorectal cancer differ from those of late-onset disease. Standardized, age-specific preventive, screening, diagnostic, and therapeutic strategies are required to optimize outcomes.
Identifiants
pubmed: 34190968
pii: 2781485
doi: 10.1001/jamasurg.2021.2380
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
865-874Subventions
Organisme : Cancer Research UK
ID : 12076
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U127527198
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA229259
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_00007/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_U127527198
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn